flying bird

Tricks and Tips

free trail

free trail
free trail

Friday, 20 July 2018


CapitalStars Investment Adviser

CEAT surges over 7.5% after 4,000% jump in Q1 profits
Tyremaker CEAT rallied over 7.5% after it posted a 4,317% jump in its Q1FY19 profits. Its net profit for the June quarter jumped to Rs72cr, as opposed to Rs1.6cr in June’17.
CEAT reported better than expected numbers in Q1FY19 aided by low base of Q1FY18 and lower raw material expenses.
Consolidated revenue was up 17% yoy at Rs1,706cr, surpassing consensus estimate of Rs1,687cr. Lower raw material and operating expenses  (as % of sales) led to tripling of EBITDA to Rs176cr, in-line with estimate.

Bajaj Auto stock drops as Q1 profit misses estimates
Shares of Bajaj Auto dropped around 9% after the company's Q1FY19 profit missed street estimates. The company has reported a 21% rise in its net profit at Rs1,115cr for the quarter ended in June 2018. It had reported a profit of Rs924cr during the corresponding quarter of last year.
Its revenue in the period increased by 27% to Rs7,419cr.

Zydus gets USFDA final approval for Spironolactone tablets USP
Zydus Cadila has received the final approval from the USFDA to market Spironolactone tablets USP (US RLD - Aldactone Tablets) in strengths of 25 mg, 50 mg, and 100 mg.
It is used to treat high blood pressure and heart failure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions like heart failure and liver disease by removing excess fluid and improving symptoms such as breathing problems.

Dr. Reddy's Lab stock advances after launching drug in US market
Dr. Reddy's Laboratories Ltd. stock gained 1.5% after the company launched Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-thecounter (OTC) therapeutic equivalent generic version of Nexium 24HR Capsules in the United States market as approved by the USFDA.
"This launch continues to demonstrate our deep R&D and manufacturing capabilities to bring newer storebrand OTC medications to the market," says Milan Kalawadia, Vice President and Head, US OTC and Speciality Rx businesses, Dr. Reddy's Laboratories.

Bajaj Finserv stock rallies ~5% after robust Q1FY19 result
Shares of Bajaj Finserv has touched 52-week high on the NSE after the company’s consolidated net profit after tax (attributable to the shareholders) for the quarter came in at Rs825.77cr, which increased by 41.3% yoy.
The revenue and the adjusted net profit of the company for the quarter were in-line with the street estimates. The estimated total revenue was Rs8,310cr and adjusted net profit was Rs789cr.


Post a Comment